Table 10.6f

Immunosuppression Use for Maintenance by Regimen

One Year Following Transplantation, 1994 to 2003

Recipients with Intestine Transplants

  Transplant Year
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 23 46 45 68 70 73 81 111 107 116
Functioning Graft at 1 Year PostTx 12 22 27 31 34 37 54 68 73 87
With Maintenance Use Recorded at 1 Year PostTx 1 6 2 7 21 36 54 68 72 86
--- + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.5% 1.4% 1.2%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 0.0% 1.2%
--- + Steroids 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 1.4% 3.5%
CyA 0.0% 16.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac 0.0% 33.3% 0.0% 57.1% 14.3% 2.8% 3.7% 26.5% 20.8% 39.5%
Tac + MMF/MPA 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.4% 0.0%
Tac + MMF/MPA + Steroids 0.0% 16.7% 0.0% 14.3% 23.8% 11.1% 9.3% 2.9% 4.2% 7.0%
Tac + OtherAntimet + Steroids 0.0% 0.0% 50.0% 0.0% 4.8% 11.1% 0.0% 2.9% 0.0% 0.0%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 2.8% 0.0% 1.5% 2.8% 1.2%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.0% 0.0% 8.3% 22.2% 7.4% 19.4% 4.7%
Tac + Steroids 100.0% 16.7% 50.0% 28.6% 57.1% 61.1% 61.1% 57.4% 45.8% 41.9%
Other Regimen 0.0% 16.7% 0.0% 0.0% 0.0% 2.8% 0.0% 0.0% 2.8% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Percentages are calculated based on the total number of patients with maintenance use at one year following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.